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Abstract
Background: Minimization of hemodynamic instability during renal replacement therapy (RRT) in patients with
acute kidney injury (AKI) is often challenging. We examined the relative hemodynamic tolerability of sustained low
efficiency dialysis (SLED) and continuous renal replacement therapy (CRRT) in critically ill patients with AKI. We also
compared the feasibility of SLED administration with that of CRRT and intermittent hemodialysis (IHD).
Methods: This cohort study encompassed four critical care units within a single university-affiliated medical centre.
77 consecutive critically ill patients with AKI who were treated with CRRT (n = 30), SLED (n = 13) or IHD (n = 34)
and completed at least two RRT sessions were included in the study. Overall, 223 RRT sessions were analyzed.
Hemodynamic instability during a given session was defined as the composite of a > 20% reduction in mean
arterial pressure or any escalation in pressor requirements. Treatment feasibility was evaluated based on the
fraction of the prescribed therapy time that was delivered. An interrupted session was designated if < 90% of the
prescribed time was administered. Generalized estimating equations were used to compare the hemodynamic
tolerability of SLED vs CRRT while accounting for within-patient clustering of repeated sessions and key
confounders.
Results: Hemodynamic instability occurred during 22 (56.4%) SLED and 43 (50.0%) CRRT sessions (p = 0.51). In a
multivariable analysis that accounted for clustering of multiple sessions within the same patient, the odds ratio for
hemodynamic instability with SLED was 1.20 (95% CI 0.58-2.47), as compared to CRRT. Session interruption
occurred in 16 (16.3), 30 (34.9) and 11 (28.2) of IHD, CRRT and SLED therapies, respectively.
Conclusions: In critically ill patients with AKI, the administration of SLED is feasible and provides comparable
hemodynamic control to CRRT.
Background
Acute kidney injury (AKI) is a frequent complication of
critical illness, and is associated with high mortality and
morbidity [1]. Using contemporary definitions for AKI,
renal replacement therapy (RRT) is required in 4-5% of
cases [1,2]. The optimal RRT modality in these patients
remains controversial.
Continuous renal replacement therapy (CRRT) has
been advocated in hemodynamically unstable patients as
a means of mitigating the blood pressure lability that
may occur with conventional intermittent hemodialysis
(IHD) [3]. However, studies directly comparing the
hemodynamic tolerability of CRRT and IHD have
yielded inconsistent results [4], and randomized con-
trolled trials have not demonstrated superior survival in
patients treated with CRRT [5-9]. While some studies
suggest that patients treated with CRRT have a higher
likelihood of renal recovery and improved renal out-
comes over the long term [10,11], this has not been pro-
ven in a randomized trial. Additionally, CRRT
implementation has several disadvantages, including the
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ing, patient immobility, intensive nursing requirements
and higher overall costs [12,13,18].
Sustained low efficiency dialysis (SLED) has emerged
as an alternative to CRRT in the management of hemo-
dynamically unstable patients with AKI. SLED is admi-
nistered using conventional dialysis technology used for
IHD but over a prolonged period (usually 8-12 hours vs
3-4 hrs with IHD), thereby allowing for the gradual
removal of fluid with less hemodynamic perturbation
than IHD. Several studies have demonstrated that SLED
is well tolerated in critically ill patients, with comparable
ultrafiltration and solute removal to CRRT [12-16].
In this study, we examined the hemodynamic toler-
ability of SLED and CRRT in critically ill individuals
with AKI. We also studied the overall feasibility of
administering various RRT modalities in this population.
Methods
Population
This is a cohort study of critically ill adults who com-
menced RRT for AKI during admission to the medical-
surgical intensive care unit (ICU), cardiovascular ICU,
trauma-neurosurgical ICU or coronary care unit at
St. Michaels’s Hospital (Toronto, Canada) between June
2007 and July 2008. In order to exclude individuals who
recovered kidney function or died shortly after RRT
initiation, we did not evaluate patients who received
only one RRT session. An RRT session was defined as
an individual treatment with IHD or SLED or as a 24-
hour period during which CRRT was prescribed. For
each patient, we included up to the first three RRT ses-
sions for these analyses. The St. Michael’sH o s p i t a l
Research Ethics Board approved the study and given the
retrospective nature of the data collection, the need for
informed consent was waived.
Description of acute renal replacement therapy
modalities
IHD and SLED were administered by hemodialysis
nurses using Phoenix™ dialysis machines (Gambro,
Richmond Hill, ON) and CA210 (Baxter, Deerfield, IL)
and Xenium 210 (Baxter, Deerfield, IL) dialyzers. Dialysate
composition and the desired ultrafiltration volume were
prescribed by the treating physicians. SLED sessions were
generally 8 hours in duration at a blood flow of 200 mL/
min and a dialysate flow of 350 mL/min. IHD sessions
were typically 3-4 hours long, with a target blood flow of
400 mL/min and a dialysate flow of 500 mL/min. CRRT,
generally administered as continuous venovenous hemo-
diafiltration, was managed by critical care unit nurses
using Prisma (Gambro, Richmond Hill, ON) and Prisma-
flex (Gambro, Richmond Hill, ON) machines. AN69-based
filters were used for all sessions with typical blood flow
rates of 100-200 mL/hour. CRRT dose was determined at
the discretion of the treating physicians and the total efflu-
ent flow rate ranged between 20-35 mL/kg/hr.
Modality assignment
RRT modality was chosen as per the clinical judgment
of the consulting nephrologist with the input of the
attending critical care physician. Patients who were per-
ceived to be hemodynamically stable were treated with
IHD. Hemodynamically unstable patients were typically
prescribed SLED or CRRT. Hemodynamic monitoring
and decisions regarding vasopressor dosing were at the
discretion of the critical care team.
Data Collection
A trained data collector compiled demographic informa-
tion, reason for ICU admission, and Charlson comorbid-
ity scores[17] on the day of RRT initiation. Bloodwork
was recorded on admission to hospital, admission to
ICU and on the day of RRT initiation. Severity of acute
illness was described using the SOFA (Sepsis-related
Organ Failure Assessment) score [18]. Systolic and dia-
stolic blood pressure and vasopressor requirements
(vasopressors included norepinephrine, phenylnephrine,
vasopressin, and epinephrine) were recorded at the
beginning and end of each RRT session. We also docu-
mented the nadir blood pressure during each treatment
session.
Endpoints
Hemodynamic instability
We defined hemodynamic instability as the composite of
the following events: an intra-treatment drop in mean
arterial pressure (MAP) of > 20% from the pre-treatment
value or the need to escalate vasopressors. The latter was
defined as the intra-treatment introduction of a vasopres-
sor or a dose increase of a vasopressor that was already in
use prior to the RRT session. Given the ap r i o r iexpecta-
tion that patients prescribed IHD as their initial modality
would be more hemodynamically stable, comparisons
pertaining to hemodynamic stability focused on indivi-
duals who received SLED or CRRT. Sensitivity analyses
were performed in which a MAP decline of > 10% or an
absolute drop in MAP to < 70 mmHg constituted hemo-
dynamic instability.
Feasibility of administration
The percentage of time during which the prescribed
RRT strategy was delivered for a treatment session was
the primary feasibility outcome, and was calculated as
t h et i m ed e l i v e r e d / t i m ep r e s c r i b e d×1 0 0 .T h ep r e -
scribed treatment time for IHD and SLED was specified
by the nephrology service. By definition, CRRT was pre-
scribed for 24 hours but if CRRT was discontinued due
to evidence of renal recovery, a decision to convert to a
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prescribed treatment time was adjusted accordingly. We
defined treatment interruption as the inability to achieve
90% of the prescribed treatment time for any given ses-
sion. We categorized the primary reason for treatment
interruption as follows: clotting of the extracorporeal
circuit, machine malfunction, hemodynamic intolerance,
nurse scheduling constraints, or patient-related. Patient-
related factors included transportation for a procedure
or diagnostic imaging, regardless of whether the inter-
ruption was planned prior to dialysis initiation. If a
patient was switched from one modality to another, the
reason for the switch was ascertained by chart review.
Statistical analysis
Patient-level comparisons were performed after categor-
izing individuals by the predominant RRT modality
received. This was the modality that was utilized for at
least two of the three analyzed sessions. Hemodynamic
and feasibility variables were evaluated during individual
treatment sessions. We compared continuous variables
using analysis of variance and categorical variables were
compared using the Fisher exact test. We evaluated the
relationship between RRT modality (SLED vs CRRT)
and hemodynamic instability using generalized estimat-
ing equations, in order to account for intra-patient clus-
tering associated with the receipt of repeated RRT
sessions. Multivariable models were adjusted for age,
gender, Charlson score, ICU type, SOFA score at RRT
initiation, baseline estimated GFR, and vasopressor
requirement prior to RRT initiation. All analyses were
performed with SAS, Version 9.1.3 (SAS, Cary, NC).
Results
During the period of observation, 101 patients received
RRT in the ICU, of whom 77 patients met the eligibility
criteria (Figure 1). We identified 34 patients who were
predominantly treated with IHD, 30 with CRRT and 13
with SLED. Three treatment sessions were available for
analysis in 69 patients and 8 patients received only 2
treatments. A total of 223 RRT sessions were analyzed.
The demographic and clinical features of the study
population are summarized in Table 1. Pre-admission
comorbidity was similar among patients treated with the
various modalities but severity of acute illness, as
reflected by the SOFA score, was substantially higher in
patients who received SLED or CRRT, as compared to
IHD. There was no significant difference in SOFA score
at RRT initiation between patients who received SLED
or CRRT (p = 0.18). Serum creatinine values at the time
of RRT initiation were significantly higher in patients
treated with IHD.
All of the CRRT sessions were delivered with some
form of anticoagulation (76% with regional citrate
anticoagulation and 24% with unfractionated heparin).
As compared to this, 95% and 75% of the SLED and
IHD sessions, respectively, were delivered without antic-
oagulation. The remainder were performed with unfrac-
tionated heparin.
Overall, 39 (51%) patients died prior to hospital dis-
charge. In-hospital mortality was 35%, 62% and 63% in
patients treated predominantly with IHD, SLED, and
CRRT, respectively.
Hemodynamic tolerability
Pre-treatment MAP was similar for CRRT and SLED
sessions (74.1 ± 10.0 vs 76.4 ± 13.1 mmHg, respectively,
p = 0.34), but pressors were employed at the onset of
therapy more frequently with CRRT (72% vs 49% for
SLED, p < 0.01). Ultrafiltration volume was similar in
both treatment groups (Table 2).
SLED therapies were more frequently associated with
a > 20% decline in MAP (38.5% vs 18.6% of CRRT ses-
sions, p = 0.02). On the other hand, pressors escalation
was observed more often during CRRT sessions (39.5%
vs 25.6% of SLED sessions, p = 0.13). Hemodynamic
instability, as defined by a composite of a MAP decline
of > 20% or a need to escalate pressors, occurred in
56.4% of SLED sessions and 50.0% of CRRT sessions
(p = 0.51). In a multivariable analysis that accounted for
intra-patient clustering, the adjusted odds ratio for
hemodynamic instability associated with SLED was 1.20
(95% CI, 0.58-2.47), as compared to CRRT.
Only one patient switched modality from SLED to
CRRT due to hemodynamic instability on SLED. This
patient completed one SLED treatment achieving a total
treatment time of 8 hours and the prescribed
7 Patients excluded because they did 
not meet criteria for AKI or were 
previously dialysis dependent
101 patients initiated RRT in the ICU 
from May 2007 until July 2008 
77 Patients received at least 2 sessions 
of RRT for AKI
17 Patients excluded because 
death/withdrawal of care occurred 
within 48 hours of RRT initiation
34 Patients were treated 
predominantly with IHD
30 Patients were treated 
predominantly with CRRT
13 Patients were treated 
predominantly with SLED
Figure 1 Flow diagram of exclusion and inclusion criteria.
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in MAP of greater than 20% and was switched to CRRT
for subsequent therapies. He then completed two CRRT
sessions achieving an ultrafiltration of 1.3 L and 2.0 L,
respectively, with no hemodynamic instability.
When the composite definition of hemodynamic
instability was modified to include a more modest MAP
reduction of 10%, or when hemodynamic instability was
simply defined as an intra-treatment nadir systolic blood
pressure of < 70 mmHg, no differences between SLED
and CRRT were noted.
Feasibility of administration
Of the prescribed treatment time, 96%, 86%, and 89%,
was delivered in IHD, SLED and CRRT, respectively
(Table 3). The proportion of sessions discontinued prior
to the delivery of 90% of the prescribed time was 16, 35
and 28%, for IHD, SLED and CRRT, respectively. Nur-
sing availability was the most common reason for treat-
ment interruption in IHD. Technical issues (eg, circuit
clotting) caused most CRRT interruptions. SLED ses-
sions were most frequently interrupted due to a need to
curtail treatment duration for patient transport out of
the ICU. Few sessions were curtailed due to hemody-
namic instability in any of the treatment modalities
Table 1 Baseline characteristics of patients divided into groups based on the predominant renal replacement modality
IHD
a
(n = 34)
CRRT
a
(n = 30)
SLED
a
(n = 13)
P-value
Male (%) 20 (58.8) 25 (83.3) 8 (61.5) 0.08
Age in years 65.4 ± 16.4 61.5 ± 17.5 63.4 ± 10.3 0.56
Charlson score 2.9 ± 2.1 2.9 ± 2.5 2.5 ± 2.2 0.83
Median serum creatinine at RRT initiation (μmol/L) 427 (326-612) 341(259-316) 390 (352-449) 0.02
Mean BUN at RRT initiation 32.9 ± 18.0 25.4 ± 13.4 27.4 ± 14.1 0.16
SOFA score at RRT initiation 9.9 ± 3.5 15.7 ± 3.6 14.0 ± 4.1 0.0001
ICU Type (%) MSICU 19(55.9) 24 (80.0) 7 (69.2) 0.16
CVICU 11 (32.4) 3 (10.0) 2 (15.4)
CCU 4 (11.8) 2 (6.7) 1 (7.7)
TNICU 0 1 (3.3) 1 (3.3)
Continuous variable are presented as mean ± SD except where indicated.
a Patients were classified according to “predominant” modality that was utilized for at least 2 of 3 sessions.
SLED = sustained low efficiency dialysis.
CRRT = continuous renal replacement therapy.
RRT = renal replacement therapy.
ICU = intensive care unit.
MSICU = Medical-Surgical Intensive Care Unit.
CVICU = Cardiovascular Intensive Care Unit.
CCU = Coronary Care Unit.
TNICU = Trauma-Neurosurgical Intensive Care Unit.
Table 2 Hemodynamic tolerability of CRRT vs SLED
CRRT (n = 86) SLED (n = 39) p-value
MAP prior to treatment session (mmHg) 74.1 ± 10.0 76.4 ± 13.1 0.34
Vasopressor requirement prior to RRT session (%) 62 (72.1) 19 (48.7) 0.01
Volume ultrafiltered per session (mL) 1823 ± 1464 1915 ± 1302 0.74
Sessions associated with > 20% reduction in MAP (%) 16 (18.6) 15 (38.5) 0.02
Sessions with vasopressor escalation
(%)
a
34 (39.5) 10 (25.6) 0.13
Unstable sessions
b (%) 43 (50.0) 22 (56.4) 0.51
Continuous variables are presented as mean ± SD. Categorical variables are presented as number of sessions (%).
SLED = sustained low efficiency dialysis.
CRRT = continuous renal replacement therapy.
MAP = mean arterial pressure.
aIncludes any increase in pressor dosage, as well as initiation of pressors.
bDefined as a treatment associated with a > 20% intra-treatment reduction in MAP or a treatment on which an escalation in pressor requirement occurred.
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3 days of therapy and the reasons for this are summar-
ized in Table 4.
Discussion
In a cohort of critically ill patients with AKI requiring
RRT, we demonstrated that the hemodynamic tolerability
of SLED did not differ significantly from CRRT. In addi-
tion, SLED was feasibly accomplished as reflected by the
delivery of over 85% of the prescribed treatment duration.
The theoretical attractiveness of CRRT emanates from
the putative ability to remove fluid and solutes in a
hemodynamically favorable manner while tailoring ultra-
filtration to the patient’s evolving clinical status. How-
ever, studies comparing CRRT and IHD, using variable
definitions of hemodynamic tolerance, have not demon-
strated a consistent hemodynamic superiority in CRRT-
treated patients [4-8] (Table 5). This fact, compounded
by the absence of a mortality benefit with CRRT [5-9]
and the logistic demands and resource intensiveness of
this modality [16,19], has impelled clinicians to seek
alternate means of providing RRT to hemodynamically
unstable patients with AKI. Using a clinically relevant
endpoint for hemodynamic instability, our findings sug-
gest that SLED is a viable alternative in the majority of
patients who would be typical candidates for CRRT.
SLED has numerous practical advantages over CRRT.
SLED can be performed without the need for systemic
anticoagulation and recent data have suggested reduced
costs as compared to CRRT [14]. The nocturnal admin-
istration of SLED, where available, allows patients to be
transported outside the critical care unit during the day-
time hours for routine tests and procedures, without
concern about interrupting the RRT session.
We observed a higher frequency of hypotensive epi-
s o d e si np a t i e n t sr e c e i v i n gS L E D ,a n dt h i sw a sc o u n -
t e r e db yat e n d e n c yf o rm o r ef r e q u e n tv a s o p r e s s o r
escalation to manage hypotension in patients receiving
CRRT. We speculate that a possible reason for this dif-
ference relates to the fact that SLED is administered by
hemodialysis nurses, who have considerably more
experience managing hypotension during dialysis ses-
sions and may be more tolerant of transient hypotensive
episodes, whereas CRRT is administered by ICU nurses
who are more accustomed to respond to altered hemo-
dynamics with vasopressor titration.
Table 3 Prescribed treatment time delivered of each RRT treatment analyzed, and reasons for early treatment
discontinuation
All modalities IHD (n = 98) CRRT
(n = 86)
SLED
(n = 39)
Percent time delivered/time prescribed 96.1 ± 8.2 85.8 ± 22.9 89.4 ± 20.5
Mean time delivered ± SD in hours 3.0 ± 0.7 19.7 ± 6.4 6.8 ± 1.8
Sessions on which < 90% of prescribed time was delivered
a 55 (24.9) 16 (16.3) 30 (34.9) 11 (28.2)
Reason for delivery of
< 90% of prescribed treatment time
Filter clotting 10 0 9 (30.0) 1 (9.1)
Machine-related 12 1 (6.7) 10 (33.3) 1 (9.1)
Hemodynamic instability 3 1 (6.7) 1 (3.3) 1 (9.1)
Patient-related 15 1 (6.7) 8 (26.7) 6 (54.6)
Nursing constraints 16 12 (80.0) 2 (6.7) 2 (18.2)
Continuous variables are presented as mean ± SD. Categorical variables are presented as number of sessions (%).
IHD = intermittent hemodialysis.
SLED = sustained low efficiency dialysis.
CRRT = continuous renal replacement therapy.
Table 4 Reasons for modality switch within first three RRT sessions, based on initial modality used
Initial modality Switched to SLED Switched to CRRT Switched to IHD
SLED – hemodynamic intolerance (n = 1)
limited nursing availability (n = 1)
improved hemodynamics (n = 3)
CRRT none – improved hemodynamics (n = 4)
IHD hemodynamic intolerance (n = 4)
deteriorated clinical status (n = 1)
hemodynamic intolerance (n = 1) –
SLED = sustained low efficiency dialysis.
CRRT = continuous renal replacement therapy.
IHD = intermittent hemodialysis.
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porting the use of SLED in critically ill patients in circum-
stances where CRRT would typically be considered.
Several studies have shown that SLED achieves adequate
solute removal with acceptable hemodynamics [12-14,16].
However, hemodynamic stability has been variably
defined. Some studies designated hemodynamic instability
by the number of hypotensive events using absolute
thresholds [12,16], while others observed changes in blood
pressure before and after dialysis sessions [12,13]. Few stu-
dies, however, accounted for concurrent use and dosing of
vasopressors during treatment. In clinical practice, drops
in blood pressure may be tempered by the introduction or
escalation of vasopressors. For this reason, we felt it was
vital to combine decrements in blood pressure and
changes in vasopressor dosing in order to arrive at a more
comprehensive and clinically meaningful definition for
hemodynamic instability.
To date, only two small trials have compared the
hemodynamic tolerability of SLED and CRRT [15,20].
These studies were small, included patients with AKI
regardless of duration of RRT dependence and in one
study [15] patients were only followed for 24 hours.
Neither study was able to demonstrate a significant dif-
ference in hemodynamic tolerability between the two
modalities. We studied SLED and CRRT in a centre
where both modalities were applied in critically ill
patients and only in the setting of hemodynamic
instability. Patients treated with SLED and CRRT had
similar blood pressure and a comparable severity of
chronic and acute illness at the onset of RRT. We also
incorporated an analytic technique that accounted for
repeated treatments within the same patient.
Our study has several limitations. Given the observa-
tional nature of this study, we cannot rule out con-
founding by indication. For example, patients treated
with CRRT were more likely to be on pressors at RRT
initiation, suggesting that they may have been less stable
than those treated with SLED. Although our findings
show that in general, the hemodynamic tolerability of
SLED and CRRT was similar, we can not rule out that
there is a subset of patients in whom CRRT is better
tolerated. The choice of RRT modality was left to the
discretion of the attending nephrologist and intensivist,
who may have had compelling reasons for their choice
which we could not capture in this retrospective analy-
sis. Future work in this area should aim to clarify factors
that inform decision-making around RRT modality.
Since SLED was administered during daytime hours in
our centre, SLED sessions were still interrupted for
patient transportation out of the critical care unit. In
addition, since this was a single centre study, our results
may not be readily applicable to other settings.
We used an arbitrary cutoff of an intra-treatment
MAP decline of 20% as part of the composite outcome
for hemodynamic instability. Nonetheless, our results
remained robust in sensitivity analyses that used differ-
ent thresholds to define instability. Finally, hemody-
namic instability, irrespective of definition, is a surrogate
endpoint and may not be predictive of patient-relevant
outcomes such as mortality and persistent dialysis
dependence. However, since there is no data to favour
one modality or another with respect to these hard end-
points, we believe that RRT-associated hypotension is a
clinically relevant endpoint as it determines whether the
therapy can be safely and practicably delivered to the
patient.
Conclusions
SLED is a well-tolerated and feasible RRT modality in
the majority of critically ill patients with AKI. Within
the limits of this observational study, SLED had compar-
able hemodynamic tolerabilty to CRRT, and was feasible
to administer with a high rate of achievement of pre-
scribed therapy duration. Larger studies will need to
clarify the impact of SLED on patient survival and kid-
ney function recovery.
Abbreviations used in this paper
SLED: sustained low efficiency dialysis; AKI: acute kidney injury; RRT: renal
replacement therapy; CRRT: continuous renal replacement therapy; IHD:
intermittent hemodialysis; ICU: intensive care unit; MAP: mean arterial
Table 5 Randomized controlled trials comparing the hemodynamic tolerability of CRRT and IHD
CRRT (n) IHD
(n)
Definition of Hemodynamic Tolerability Outcome
Misset et al
a[4] 27 27 Amplitude of MAP change (lowest recorded every hour to highest
recorded), and episodes of MAP reduction by > 10 mmHg
No significant difference (p = 0.72
and 0.73, respectively)
Augustine et al [6] 40 40 Difference between mean MAP in 12 hours
prior to RRT and during RRT
Significant drop in MAP during
IHD (p = 0.04)
Uehlinger et al [7] 70 55 Number of hypotensive events (MAP < 65) during RRT No significant difference
(p = 0.36)
Vinsonneau et al [8] 175 184 Number of hypotensive events (SBP < 80, or drop of
greater than 50 mmHg) during RRT
No significant difference
(p = 0.47)
aA cross-over study with a 24-hour wash-out period.
MAP, mean arterial pressure; SBP, systolic blood pressure.
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Page 6 of 7pressure; GFR: glomerular filtration rate; SOFA: sepsis-related organ failure
assessment; RCT: randomized controlled trial.
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